Real-World Analysis of Rapid-Acting Insulin Analog Use and Its Blood Glucose Lowering Effect in Patients with Type 2 Diabetes Mellitus: Results from PASSION Disease Registry in Korea

Hye Soon Kim; Jae Myung Yu; Hak Chul Jang; Eui Kwang Choi; Jeong Hyun Park; Ho Sang Shon; Choon Hee Chung; Keun Gyu Park; Jae Hyoung Cho; Won Kim; Kyoung Hwa Lee; Jee Hyun Lee; Soon Jib Yoo

doi:10.2147/DMSO.S334944

Real-World Analysis of Rapid-Acting Insulin Analog Use and Its Blood Glucose Lowering Effect in Patients with Type 2 Diabetes Mellitus: Results from PASSION Disease Registry in Korea

Hye Soon Kim, Jae Myung Yu, Hak Chul Jang, Eui Kwang Choi, Jeong Hyun Park, Ho Sang Shon, Choon Hee Chung, Keun Gyu Park, Jae Hyoung Cho, Won Kim, Kyoung Hwa Lee, Jee Hyun Lee, Soon Jib Yoo

Internal Medicine

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Purpose: Although rapid-acting insulins (RAIs) are used frequently in Korean clinical settings, evidence on their use is limited. This study explores the pattern and clinical effectiveness of the use of RAIs in Korean patients with type 2 diabetes mellitus (T2DM). Patients and Methods: This non-interventional, observational study enrolled patients (aged >18 years) with T2DM who were prescribed RAIs. The pattern of use and effectiveness of RAI analogs were evaluated over 6 months. Results: A total of 299/451 patients were analyzed. Approximately 90% (n/N=270/299) of the patients received insulin glulisine, which significantly reduced their levels of glycated hemoglobin (HbA1c: n=270, mean± standard deviation [SD]; −1.16±6.02%, p=0.0017), fasting plasma glucose (n=40; mean±SD: −54.9±90.89 mg/dl, p=0.0005), and post prandial blood glucose (n=35, mean±SD: −89.46± 105.68 mg/dl, p<0.0001) at 6 months, with a corresponding increase in body weight (BW) (n=197, mean±SD:1.45±3.64 kg, p<0.0001). At 6 months, more patients receiving an intensive regimen (basal insulin+≥2 RAI injections/day) had HbA1c <7% than those receiving a non-intensive regimen (basal insulin+1 RAI injection/day) (20.69% vs 7.46%; p=0.0333); the corresponding reduction in HbA1c was also higher in patients receiving the intensive regimen (p<0.0001). About one-fourth patients (n/N=22/95) were switched to the intensive regimen (from 1 to ≥2 RAI injections/day), and only 4.41% (n/N=9/204) of the patients were switched to 1 RAI injection/day. The patients receiving the intensive regimen showed higher levels of HbA1c reductions (mean±SD: −1.27±1.96%) compared with the maintenance group-1 RAI injection/day (mean±SD: −0.72±1.66%) (p=0.0459), without a significant increase in BW and body mass index. Conclusion: The insulin glulisine intensification regimen showed glycemic target achievement and can be considered a therapeutic tool in the management of T2DM patients.

Original language	English
Pages (from-to)	1495-1503
Number of pages	9
Journal	Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Volume	15
DOIs	https://doi.org/10.2147/DMSO.S334944
Publication status	Published - 2022

Bibliographical note

Funding Information:
The authors would like to thank the study patients, their family, and caregivers who were involved in this study. Editorial support in the preparation of this publication was provided by Sonal More (Tata Consultancy Services Ltd., India) and paid for by Sanofi. Editorial support in the preparation of this publication was also provided by Anahita Gouri and Rohan Mitra of Sanofi, India. The authors, individually and collectively, are responsible for all content and editorial decisions and received no payment from Sanofi directly or indirectly (through a third party) related to the development/presentation of this publication. Funding The study was funded by Sanofi Aventis Korea Ltd.

Funding Information:
The study was funded by Sanofi Aventis Korea Ltd.

Publisher Copyright:
© 2022 Kim et al.

All Science Journal Classification (ASJC) codes

Internal Medicine
Pharmacology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2147/DMSO.S334944

Cite this

Kim, H. S., Yu, J. M., Jang, H. C., Choi, E. K., Park, J. H., Shon, H. S., Chung, C. H., Park, K. G., Cho, J. H., Kim, W., Lee, K. H., Lee, J. H., & Yoo, S. J. (2022). Real-World Analysis of Rapid-Acting Insulin Analog Use and Its Blood Glucose Lowering Effect in Patients with Type 2 Diabetes Mellitus: Results from PASSION Disease Registry in Korea. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 15, 1495-1503. https://doi.org/10.2147/DMSO.S334944

@article{6a1e10efa6094ea39de386504b52945e,

title = "Real-World Analysis of Rapid-Acting Insulin Analog Use and Its Blood Glucose Lowering Effect in Patients with Type 2 Diabetes Mellitus: Results from PASSION Disease Registry in Korea",

abstract = "Purpose: Although rapid-acting insulins (RAIs) are used frequently in Korean clinical settings, evidence on their use is limited. This study explores the pattern and clinical effectiveness of the use of RAIs in Korean patients with type 2 diabetes mellitus (T2DM). Patients and Methods: This non-interventional, observational study enrolled patients (aged >18 years) with T2DM who were prescribed RAIs. The pattern of use and effectiveness of RAI analogs were evaluated over 6 months. Results: A total of 299/451 patients were analyzed. Approximately 90% (n/N=270/299) of the patients received insulin glulisine, which significantly reduced their levels of glycated hemoglobin (HbA1c: n=270, mean± standard deviation [SD]; −1.16±6.02%, p=0.0017), fasting plasma glucose (n=40; mean±SD: −54.9±90.89 mg/dl, p=0.0005), and post prandial blood glucose (n=35, mean±SD: −89.46± 105.68 mg/dl, p<0.0001) at 6 months, with a corresponding increase in body weight (BW) (n=197, mean±SD:1.45±3.64 kg, p<0.0001). At 6 months, more patients receiving an intensive regimen (basal insulin+≥2 RAI injections/day) had HbA1c <7% than those receiving a non-intensive regimen (basal insulin+1 RAI injection/day) (20.69% vs 7.46%; p=0.0333); the corresponding reduction in HbA1c was also higher in patients receiving the intensive regimen (p<0.0001). About one-fourth patients (n/N=22/95) were switched to the intensive regimen (from 1 to ≥2 RAI injections/day), and only 4.41% (n/N=9/204) of the patients were switched to 1 RAI injection/day. The patients receiving the intensive regimen showed higher levels of HbA1c reductions (mean±SD: −1.27±1.96%) compared with the maintenance group-1 RAI injection/day (mean±SD: −0.72±1.66%) (p=0.0459), without a significant increase in BW and body mass index. Conclusion: The insulin glulisine intensification regimen showed glycemic target achievement and can be considered a therapeutic tool in the management of T2DM patients.",

author = "Kim, {Hye Soon} and Yu, {Jae Myung} and Jang, {Hak Chul} and Choi, {Eui Kwang} and Park, {Jeong Hyun} and Shon, {Ho Sang} and Chung, {Choon Hee} and Park, {Keun Gyu} and Cho, {Jae Hyoung} and Won Kim and Lee, {Kyoung Hwa} and Lee, {Jee Hyun} and Yoo, {Soon Jib}",

note = "Funding Information: The authors would like to thank the study patients, their family, and caregivers who were involved in this study. Editorial support in the preparation of this publication was provided by Sonal More (Tata Consultancy Services Ltd., India) and paid for by Sanofi. Editorial support in the preparation of this publication was also provided by Anahita Gouri and Rohan Mitra of Sanofi, India. The authors, individually and collectively, are responsible for all content and editorial decisions and received no payment from Sanofi directly or indirectly (through a third party) related to the development/presentation of this publication. Funding The study was funded by Sanofi Aventis Korea Ltd. Funding Information: The study was funded by Sanofi Aventis Korea Ltd. Publisher Copyright: {\textcopyright} 2022 Kim et al.",

year = "2022",

doi = "10.2147/DMSO.S334944",

language = "English",

volume = "15",

pages = "1495--1503",

journal = "Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy",

issn = "1178-7007",

publisher = "Dove Medical Press Ltd.",

}

Kim, HS, Yu, JM, Jang, HC, Choi, EK, Park, JH, Shon, HS, Chung, CH, Park, KG, Cho, JH, Kim, W, Lee, KH, Lee, JH & Yoo, SJ 2022, 'Real-World Analysis of Rapid-Acting Insulin Analog Use and Its Blood Glucose Lowering Effect in Patients with Type 2 Diabetes Mellitus: Results from PASSION Disease Registry in Korea', Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, vol. 15, pp. 1495-1503. https://doi.org/10.2147/DMSO.S334944

Real-World Analysis of Rapid-Acting Insulin Analog Use and Its Blood Glucose Lowering Effect in Patients with Type 2 Diabetes Mellitus : Results from PASSION Disease Registry in Korea. / Kim, Hye Soon; Yu, Jae Myung; Jang, Hak Chul et al.

In: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol. 15, 2022, p. 1495-1503.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Real-World Analysis of Rapid-Acting Insulin Analog Use and Its Blood Glucose Lowering Effect in Patients with Type 2 Diabetes Mellitus

T2 - Results from PASSION Disease Registry in Korea

AU - Kim, Hye Soon

AU - Yu, Jae Myung

AU - Jang, Hak Chul

AU - Choi, Eui Kwang

AU - Park, Jeong Hyun

AU - Shon, Ho Sang

AU - Chung, Choon Hee

AU - Park, Keun Gyu

AU - Cho, Jae Hyoung

AU - Kim, Won

AU - Lee, Kyoung Hwa

AU - Lee, Jee Hyun

AU - Yoo, Soon Jib

N1 - Funding Information: The authors would like to thank the study patients, their family, and caregivers who were involved in this study. Editorial support in the preparation of this publication was provided by Sonal More (Tata Consultancy Services Ltd., India) and paid for by Sanofi. Editorial support in the preparation of this publication was also provided by Anahita Gouri and Rohan Mitra of Sanofi, India. The authors, individually and collectively, are responsible for all content and editorial decisions and received no payment from Sanofi directly or indirectly (through a third party) related to the development/presentation of this publication. Funding The study was funded by Sanofi Aventis Korea Ltd. Funding Information: The study was funded by Sanofi Aventis Korea Ltd. Publisher Copyright: © 2022 Kim et al.

PY - 2022

Y1 - 2022

N2 - Purpose: Although rapid-acting insulins (RAIs) are used frequently in Korean clinical settings, evidence on their use is limited. This study explores the pattern and clinical effectiveness of the use of RAIs in Korean patients with type 2 diabetes mellitus (T2DM). Patients and Methods: This non-interventional, observational study enrolled patients (aged >18 years) with T2DM who were prescribed RAIs. The pattern of use and effectiveness of RAI analogs were evaluated over 6 months. Results: A total of 299/451 patients were analyzed. Approximately 90% (n/N=270/299) of the patients received insulin glulisine, which significantly reduced their levels of glycated hemoglobin (HbA1c: n=270, mean± standard deviation [SD]; −1.16±6.02%, p=0.0017), fasting plasma glucose (n=40; mean±SD: −54.9±90.89 mg/dl, p=0.0005), and post prandial blood glucose (n=35, mean±SD: −89.46± 105.68 mg/dl, p<0.0001) at 6 months, with a corresponding increase in body weight (BW) (n=197, mean±SD:1.45±3.64 kg, p<0.0001). At 6 months, more patients receiving an intensive regimen (basal insulin+≥2 RAI injections/day) had HbA1c <7% than those receiving a non-intensive regimen (basal insulin+1 RAI injection/day) (20.69% vs 7.46%; p=0.0333); the corresponding reduction in HbA1c was also higher in patients receiving the intensive regimen (p<0.0001). About one-fourth patients (n/N=22/95) were switched to the intensive regimen (from 1 to ≥2 RAI injections/day), and only 4.41% (n/N=9/204) of the patients were switched to 1 RAI injection/day. The patients receiving the intensive regimen showed higher levels of HbA1c reductions (mean±SD: −1.27±1.96%) compared with the maintenance group-1 RAI injection/day (mean±SD: −0.72±1.66%) (p=0.0459), without a significant increase in BW and body mass index. Conclusion: The insulin glulisine intensification regimen showed glycemic target achievement and can be considered a therapeutic tool in the management of T2DM patients.

AB - Purpose: Although rapid-acting insulins (RAIs) are used frequently in Korean clinical settings, evidence on their use is limited. This study explores the pattern and clinical effectiveness of the use of RAIs in Korean patients with type 2 diabetes mellitus (T2DM). Patients and Methods: This non-interventional, observational study enrolled patients (aged >18 years) with T2DM who were prescribed RAIs. The pattern of use and effectiveness of RAI analogs were evaluated over 6 months. Results: A total of 299/451 patients were analyzed. Approximately 90% (n/N=270/299) of the patients received insulin glulisine, which significantly reduced their levels of glycated hemoglobin (HbA1c: n=270, mean± standard deviation [SD]; −1.16±6.02%, p=0.0017), fasting plasma glucose (n=40; mean±SD: −54.9±90.89 mg/dl, p=0.0005), and post prandial blood glucose (n=35, mean±SD: −89.46± 105.68 mg/dl, p<0.0001) at 6 months, with a corresponding increase in body weight (BW) (n=197, mean±SD:1.45±3.64 kg, p<0.0001). At 6 months, more patients receiving an intensive regimen (basal insulin+≥2 RAI injections/day) had HbA1c <7% than those receiving a non-intensive regimen (basal insulin+1 RAI injection/day) (20.69% vs 7.46%; p=0.0333); the corresponding reduction in HbA1c was also higher in patients receiving the intensive regimen (p<0.0001). About one-fourth patients (n/N=22/95) were switched to the intensive regimen (from 1 to ≥2 RAI injections/day), and only 4.41% (n/N=9/204) of the patients were switched to 1 RAI injection/day. The patients receiving the intensive regimen showed higher levels of HbA1c reductions (mean±SD: −1.27±1.96%) compared with the maintenance group-1 RAI injection/day (mean±SD: −0.72±1.66%) (p=0.0459), without a significant increase in BW and body mass index. Conclusion: The insulin glulisine intensification regimen showed glycemic target achievement and can be considered a therapeutic tool in the management of T2DM patients.

UR - http://www.scopus.com/inward/record.url?scp=85130556898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85130556898&partnerID=8YFLogxK

U2 - 10.2147/DMSO.S334944

DO - 10.2147/DMSO.S334944

M3 - Article

AN - SCOPUS:85130556898

SN - 1178-7007

VL - 15

SP - 1495

EP - 1503

JO - Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

JF - Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

ER -

Real-World Analysis of Rapid-Acting Insulin Analog Use and Its Blood Glucose Lowering Effect in Patients with Type 2 Diabetes Mellitus: Results from PASSION Disease Registry in Korea

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this